Orlistat and sibutramine beyond weight loss

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 5, 2008, Pages 342-348

  Mannucci, Edoardo ^a   Dicembrini, Ilaria ^a   Rotella, Francesco ^a   Rotella, Carlo Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cardiovascular risk; Lipid profile; Orlistat; Sibutramine; Total cholesterol; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; LIPID; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; ANTILIPEMIC AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; HYPERLIPIDEMIAS; LACTONES; LIPIDS; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 44349172471     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.03.010     Document Type: Article

References (45)

1. Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Al Mamun A., Bonneux L., et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 138 (2003) 24-32
2. Wing R.R., Koeske R., Epstein L.H., Nowalk M.P., Gooding W., and Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147 (1987) 1749-1753
3. Kelly D.E., Wing R., Buonocore C., Sturis J., Polonsky K., and Fitzimmons M. Relative effects of caloric restrictions and weight loss in non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77 (1993) 1287-1293
4. Sjostrom C.D., Peltonen M., Wedel H., and Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36 (2000) 20-25
5. The Trials of Hypertension Prevention collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal pressure: the trials of hypertension prevention, phase II. Arch Intern Med 157 (1997) 657-667
6. Martens I.L., and Van Gaal L.F. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 8 3 (2000) 270-278
7. Moore L.L., Visioni A.J., Qureshi M.M., Bradlee M.L., Ellison R.C., and D'Agostino R. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham Study. Arch Intern Med 165 11 (2005) 1298-1303
8. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 6 suppl. 2 (1998) 51S-209S
9. Dattilo A.M., and Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56 (1992) 320-328
10. Hutton B., and Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 80 (2004) 1461-1468
11. Avenell A., Brown T.J., McGee M.A., Campbell M.K., Grant A.M., Broom J., et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Dietet 17 (2004) 293-316
12. Jadad A.R., Moore R.A., Carrol D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials 17 1 (1996) 1-12
13. Hanefeld M., and Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 4 (2002) 415-423
14. Kelley D.E., Bray G.A., Pi-Sunyer F.X., Klein S., Hill J., Miles J., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 25 (2002) 1033-1041
15. Miles J., Letter L., Hollander P., Wadden T., Anderson J.W., Doyle M., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25 (2002) 1123-1128
16. Lucas P., Boldrin M.N., and Reaven G.M. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 91 (2003) 961-964
17. Derosa G., Mugellini A., Ciccarelli L., and Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both, on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed as a standardized diet. Clin Ther 25 (2003) 1107-1122
18. Erdmann J., Lippl F., Klose G., and Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment -efficacy and limitations. Aliment Pharmacol Ther 19 (2004) 1173-1179
19. Muls E., Kolanowski J., Scheen A., and Van Gaal L. The effect of orlistat on weight and serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 25 (2001) 1713-1721
20. Broom I., Hughes E., Dodson P., and Reckless J. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolemia: consequences for coronary risk. Br J Cardiol 9 (2002) 460-468
21. Rossner S., Sjostrom L., Noack R., Meinders E., and Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 8 (2000) 49-61
22. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Intern Med 248 (2000) 245-254
23. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 27 (2004) 155-161
24. Zavoral J.H. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 16 (1998) 2013-2017
25. Sjostrom L., Rissanen A., Andersen T., Boldrin M., Golay A., Kopperschaar, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352 (1998) 167-172
26. Hauptman J., Lucas C., Boldrin M.N., Collins H., and Segal K.R. Orlistat in long-term treatment of obesity in primary care settings. Arch Fam Med 9 (2000) 160-167
27. Hill J.O., Hauptman J., Anderson J.W., Fujioka K., O'Neil P.M., Smith D.K., et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 69 (1999) 1108-1116
28. Serrano-Rios M., Melchionda N., and Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19 (2002) 119-124
29. McNulty S., Ur E., and Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26 (2003) 125-131
30. Sanchez-Reyes L., Fangh G., Yamamoto J., Martinez-Rivas L.N., Campos-Franco E., and Berber A. Use of sibutramine in overweight Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 26 (2004) 1427-1435
31. Gokcel A., Karakose H., Ertorer E.M., Tanaci N., Tutuncu N.B., and Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 24 (2001) 1957-1960
32. Fujioka K., Seaton T.B., Rowe E., Jelinek C.A., Raskin P., Lebovitz H.E., et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2 (2000) 175-187
33. Dujovne C., Zavoral J.H., Rowe E., and Mendel C.M. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 142 (2001) 489-497
34. Faria A.N., Ribeiro Filho F., Kohlmann E., Gouvea Ferreira R., and Zanella M.T. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 7 (2004) 246-253
35. Halpern A., Leite C.C., Herszkowicz, Barbato A., and Arruda Costa A.P. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. Rev Hosp Clin Fac Med S Paulo 57 (2002) 98-102
36. Tambascia M.A., Geloneze B., Repetto E.M., Geloneze S.R., Picolo M., and Magro D.O. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 5 (2003) 338-344
37. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jasn A.K., Mendel C.M., et al. Sibutramine produces dose-related weight loss. Obes Res 2 (1999) 189-197
38. De Simone G., Romano C., De Caprio C., Contaldo F., Salanitri T., di Luzio Paparatti U., et al. Effects of Sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 15 (2005) 24-30
39. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Regulation of triglycerides in insulin resistance and diabetes. Arch Med Res 36 3 (2005) 232-240
40. Sartorio A., Lafortuna C.L., Vangeli V., Tavani A., Bosetti C., and La Vecchia C. Short-term changes of cardiovascular risk factors after non-pharmacological body weight reduction program. Eur J Clin Nutr 55 (2001) 865-869
41. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
42. Tighe D.A., Ockene I.S., Reed G., and Nicolosi R. Calculated low density cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels ≤4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with Friedewald calculation. Clin Chim Acta 365 1-2 (2006) 236-242
43. Mittendorfer B., Ostlund R.E., Patterson B.W., and Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 9 10 (2001) 599-604
44. Corradini S.G., Eramo A., Lubrano C., Spera G., Cornoldi A., Grossi A., et al. Comparison of changes in lipid profile after bilio-intestinal bypass and gastric banding in patients with morbid obesity. Obes Surg 11 (2005) 367-377
45. Snow V., Barry P., Fitterman N., Qaseem A., and Weiss K. Pharmacologic and surgical management of obesity in Primary Care: a clinical practice guideline from American College of Physicians. Ann Intern Med 142 (2005) 525-531